# Elektrofi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elektrofi

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.elektrofi.com
- Total disclosed funding: $155M
- Latest round: Series C (Aug 8, 2024)
- Investors on record: 20

## About

Founded in 2016 and based in Massachusetts, US, Elektrofi, Inc. operates as a biotechnology company that develops a range of biologic therapies through a formulation platform that utilizes proprietary microparticle technology for monoclonal antibodies, therapeutic proteins, and other large molecule drugs. In October 2024, Elektrofi, Inc. raised USD 112.25 million in series C funding co-led by new investors Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG, with participation from other new investors Eli Lilly and Company, Braidwell Lp, Catalio Capital Management, Checkpoint Capital, Deep Track Capital, General Catalyst Partners, Kearny Venture Partners, Paradigm Biocapital Advisors, Samsara Biocapital, Woodline Partners, and Leerink Partners. Returning investors BVF Partners, Janus Henderson Investors, Logos Capital, and Marshall Wace also participated in the round. As of June 2022, Elektorofi is led by co-founder and CEO, Chase Coffman. Elektrofi's offers a proprietary microparticle technology platform that enables patient-friendly small-volume subcutaneous injections for monoclonal antibodies, therapeutic proteins, and other large-molecule drugs which are more convenient than intravenous infusions. The company's products include prefilled syringes, pen injectors, and autoinjectors. Elektrofi's partners include LEO, Sanofi, NSF, and NIIMBL. The company plans to use a portion of the Series B proceeds to establish a centralized GMP manufacturing line in support of multiple clinical trials. It also plans to double employee headcount over the next 12-18 months to accelerate development across a pipeline of licensed programs.

In October 2025, Halozyme, Inc. agreed to acquire Elektrofi from Braidwell Lp, BVF Partners, Catalio Capital Management, Checkpoint Capital, Deep Track Capital, Eli Lilly & Company, General Catalyst Partners, Janus Henderson Investors, Kearny Venture Partners, Leerink Partners, Logos Capital, Marshall Wace, Novo Holdings, Paradigm BioCapital, RA Capital, Royalty Pharma, Samsara BioCapital, SR One, TPG, and Woodline Partners for USD 750 million and USD 150 million milestone payments.

The acquisition aims to expand Halozyme, Inc.’s drug delivery technology portfolio by integrating a microparticle formulation platform for high-concentration biologics.

## Funding rounds

- Series C, Aug 8, 2024, $112M — TPG, General Catalyst Partners, SR One, Novo Holdings, Kearny Venture Partners, Marshall Wace, Royalty Pharma, Leerink Partners, Eli Lilly & Company, BVF Partners, RA Capital Management, Janus Henderson Investors, Samsara BioCapital, Woodline Partners, Logos Capital, Catalio Capital Management, Paradigm BioCapital, Deep Track Capital, Braidwell Lp, Checkpoint Capital
- Series B, May 27, 2022, $43M — Marshall Wace, BVF Partners, Janus Henderson Investors, Logos Capital

## Investors

- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series B, Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B, Series C
- Janus Henderson Investors — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B, Series C
- TPG (https://capitalatlas.ai/funds/tpg) — Series C
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Novo Holdings — Series C
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series C
- Royalty Pharma (https://capitalatlas.ai/funds/royalty-pharma) — Series C
- Leerink Partners — Series C
- Eli Lilly & Company — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C
- Woodline Partners — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C
- Paradigm BioCapital — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C
- Braidwell Lp — Series C
- Checkpoint Capital — Series C